Prévisions
L'objectif de cours moyen des analystes est de 13,67 € (+395,29 %). La médiane est de 13,67 € (+395,29 %).
| Acheter |
4 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Armata Pharmaceuticals rises after FDA decision naming AP-SA02 a "Breakthrough Therapy"
Armata Pharmaceuticals’ stock rose sharply after the FDA granted the phage candidate AP-SA02 "Breakthrough Therapy" status for the adjuvant treatment of complicated Staphylococcus aureus bacteremia. The designation is based on phase 1b/2a data in which 100% of patients treated with AP-SA02 showed a sustained clinical response 28 days after end of therapy versus 75% in the placebo group. AP-SA02 also received Fast Track and Qualified Infectious Disease Product designations; the treatment was well tolerated without serious adverse events attributable to the product. » Plus sur de.investing.com
Armata submits phase‑3 protocol for AP‑SA02 against resistant staphylococci to FDA
Armata has filed the complete phase‑3 protocol and responses to FDA feedback for the bacteriophage candidate AP‑SA02 to treat complicated S. aureus bacteremias. Four engineering runs have been completed in cGMP production in Los Angeles; production of clinical trial material and study start are planned for the second half of 2026. AP‑SA02 holds FDA designations Qualified Infectious Disease Product and Fast Track; the U.S. Department of Defense is funding development with an additional $2.5 million (total $28.7 million). Investors reacted positively, the share price rose markedly, and David House was promoted to CFO. » Plus sur de.investing.com
Armata receives fast-track status from FDA for phage drug AP-SA02
The FDA has granted fast-track status to Armata’s intravenous multi-phage candidate AP-SA02 for the treatment of complicated S. aureus bacteremias, enabling more frequent interaction with the agency, rolling review of approval, and potentially accelerated approval. AP-SA02 showed positive Phase 1b/2a results, and Armata plans a Phase 3 superiority study in the second half of 2026. Analysts mostly rate the stock a buy with price targets of $15 to $20, although the company was recently unprofitable and reported a loss per share of $4.80. » Plus sur de.investing.com
Armata Pharmaceuticals schedules annual general meeting for June 11
Armata Pharmaceuticals has scheduled its annual general meeting for June 11, 2026 at 8:30 a.m. Pacific Time at its headquarters in Los Angeles. Shareholders eligible to receive notice and vote are those recorded in the share register at the close of business on April 17, 2026; the deadline for shareholder proposals and director nominations is April 12, 2026 at 5:00 p.m. Pacific Time. The company also reported weak quarterly results: adjusted EPS of -$3.42 and revenue of $1.1 million, both well below expectations. » Plus sur de.investing.com
Armata Pharmaceuticals: stock falls after delay of quarterly report despite FDA status for AP-SA02
Armata Pharmaceuticals delays publication of its Q4 and full-year 2025 report and expects to file the 10-K by no later than March 31, 2026, after which the stock dropped sharply. The FDA has granted the phage candidate AP-SA02 QIDP status, providing development incentives and the possibility of a five-year extension of market exclusivity; a Fast Track application has been submitted. The FDA considers the phase-2a data sufficient to start a phase-3 trial, planned to begin in the second half of 2026. In addition, the cGMP manufacturing facility in Los Angeles has been commissioned; market capitalization is around $310.91 million and an analysis suggests possible overvaluation. » Plus sur de.investing.com
Données financières
Au dernier trimestre, Armata Pharmaceuticals a réalisé un chiffre d'affaires de 2,8 M € et un bénéfice net de 48,43 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 2,8 M | - |
| Bénéfice brut | 2,29 M | - |
| Bénéfice net | 48,43 M | 313,06 % |
| EBITDA | 55,61 M | 397,19 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 107,45 M € |
Nombre d'actions | 37,19 M |
Plus haut/bas sur 52 semaines | 13,65 € - 2,19 € |
| Dividendes | Non |
Bêta | 1,41 |
Ratio P/E | -0,93 |
Ratio PEG | 0,00 |
Ratio P/B | 0,00 |
Ratio P/S | 18,22 |
Profil de l'entreprise
Armata Pharmaceuticals, Inc., une société de biotechnologie au stade clinique, se concentre sur le développement de thérapeutiques ciblées à base de bactériophages destinées aux infections résistantes aux antibiotiques dans le monde entier. Elle développe ses produits à l'aide de sa technologie propriétaire fondée sur les bactériophages. Les candidats-médicaments de la société comprennent AP-SA02, destiné au traitement de la bactériémie à Staphylococcus aureus ; AP-PA02, destiné à Pseudomonas aeruginosa ; et AP-PA03, destiné au traitement de la pneumonie. Elle a conclu un accord de partenariat avec Merck & Co. pour le développement de bactériophages synthétiques destinés à cibler des agents infectieux non divulgués. La société a son siège social à Marina del Rey, en Californie.
| Nom | Armata Pharmaceuticals |
| PDG | Deborah L. Birx |
| Siège social | Los Angeles,
ca États-Unis |
| Site web | |
| Secteur | Consommation de base |
| Industrie | Produits alimentaires |
| Introduction en bourse | 20/05/1994 |
| Employés | 61 |
Deep Dive
Symboles boursiers
| Bourse | Symbole |
|---|---|
AMEX | ARMP |
Frankfurt | TG1N.F |
München | TG1N.MU |
Düsseldorf | TG1N.DU |